How would you manage a CLL patient who experienced severe infusion reactions with rituximab and has exhausted all other options?  

This is a relatively common question and very relevant to clinical care. Rituximab, Ofatumumab, and Obinutuzumab do target CD20 but all should be viewed as we would view different structural classes of drugs. In general, if one has a very bad reaction to rituximab, depending upon what it is, one can...